Daré Bioscience, Inc. (NASDAQ:DARE) Sees Significant Growth in Short Interest

Daré Bioscience, Inc. (NASDAQ:DAREGet Free Report) was the recipient of a significant growth in short interest in April. As of April 15th, there was short interest totalling 246,900 shares, a growth of 5.1% from the March 31st total of 235,000 shares. Based on an average daily trading volume, of 438,000 shares, the short-interest ratio is presently 0.6 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Daré Bioscience stock. Armistice Capital LLC purchased a new stake in shares of Daré Bioscience, Inc. (NASDAQ:DAREFree Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned approximately 7.37% of Daré Bioscience at the end of the most recent quarter. 6.70% of the stock is currently owned by institutional investors and hedge funds.

Daré Bioscience Stock Down 5.4 %

Shares of NASDAQ:DARE opened at $0.31 on Friday. The firm has a fifty day moving average of $0.45 and a two-hundred day moving average of $0.39. The firm has a market capitalization of $31.38 million, a P/E ratio of -0.92 and a beta of 1.31. Daré Bioscience has a 12-month low of $0.27 and a 12-month high of $1.06.

Daré Bioscience (NASDAQ:DAREGet Free Report) last issued its earnings results on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06. The company had revenue of $1.81 million for the quarter, compared to analyst estimates of $2.17 million. Equities research analysts expect that Daré Bioscience will post -0.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DARE. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Daré Bioscience in a report on Wednesday. Dawson James cut shares of Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th. Finally, Brookline Capital Management lowered shares of Daré Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, April 17th.

View Our Latest Stock Report on DARE

Daré Bioscience Company Profile

(Get Free Report)

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.

Featured Articles

Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.